Disease Landscape and Forecast Insights

Complex regional pain syndrome (CRPS) is a debilitating pain condition characterized by persistent pain, typically in distal limbs, with intensity and symptomology disproportionate to any…

Immune checkpoint inhibitors have transformed the treatment algorithm for recurrent or metastatic non-nasopharyngeal squamous cell carcinoma of the head and neck (SCCHN) and diversified treatment…

The FDA approval of five immune checkpoint inhibitors for advanced or metastatic bladder cancer has significantly altered the treatment landscape, which has historically been dominated by…

Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by diarrhea, abdominal pain, and weight loss. The primary goal of CD treatment is to induce and…

Colorectal cancer, a major public health concern in China, is expected to become the second-most-common form of cancer there by 2029, behind only lung cancer. The treatment of metastatic colorectal…

MARKET OUTLOOK China has the highest incidence of gastric cancer (gastric and gastroesophageal junction adenocarcinoma) in the world, and therapeutic options are limited. Only two targeted…

The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 400 currently available and novel biosimilar products, detailing…

Hepatocellular carcinoma (HCC) is a primary malignancy of the liver that commonly arises from underlying liver cirrhosis. Nexavar (Bayer HealthCare / Amgen / Onyx), an angiogenesis inhibitor, was…

The incidence of gastroesophageal cancer—encompassing gastric cancer, esophageal cancer, and gastroesophageal junction (GEJ) adenocarcinoma— continues to rise; however, treatment options remain…

Heart failure (HF) can be categorized into acute or chronic, and we focus on both settings in this report. HF patients are subject to high rates of mortality and morbidity. While much progress…

The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics and grow steadily over the next decade. The well-established TNF-α inhibitors (e.g., Janssen/Merck’s…

Colorectal cancer is the third-most-common cancer globally, and metastatic disease is associated with poor five-year overall survival rates. Current treatment for metastatic colorectal cancer is…